Cancer Therapy

Role of nucleoside transporters in uptake-mediated cancer therapy clarified

Published in Clinical Oncology Week, August 21st, 2006

A recently published study from Canada has reported on the role of human nucleoside transporters in cellular uptake of 4'-thio-beta-D-arabinofuranosyl cytosine (TaraC) and beta-D-arabinosylcytosine (araC).

"TaraC is in phase I development for treatment of cancer," wrote M.L. Clarke and colleagues, Cross Cancer Institute.

"In human equilibrative nucleoside transporter (hENT) 1-containing CEM cells, initial rates of uptake (10 mcM; picomoles per microliter of cell water per second) of [H-3] TaraC and [H-3] araC were low (0.007±003 and 0.034±0.003, respectively) compared with that of [H-3] uridine (0.317±0.048), a high-activity...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Clinical Oncology Week

Source: Clinical Oncology Week (2006-08-21)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry